

# Revised Draft Agenda Biocides Working Group Meeting I – 2015 Virtual meetings via AdobeConnect

### January 26 - 30, 2015

Monday 26 January	10:30-13:00	APCP WG (Virtual meeting)
	14:00-18:00	
Tuesday 27 January	10:30-13:00	TOX WG (Virtual meeting)
	14:00-18:00	If necessary, to be continued on <b>Wed 28 January at 10:30</b> in parallel with EFF WG.
Wednesday 28 January	10:30-13:00	EFF WG (Virtual meeting)
	14:00-18:00	
Thursday 29 January	12:00-13:00	ENV WG (Virtual meeting)
	14:00-18:00	
Friday 30 January	10:30-13:00	ENV WG (Virtual meeting)
	14:00-16:00	

### Analytical methods and physico-chemical properties Working Group

**Chair: Bernhard Krebs** 

### Item 1 - Welcome and apologies

### Item 2 - Administrative issues

For information

### Item 3 - Agreement of the agenda

For agreement

### Item 4 – Declarations of potential conflicts of interest in relation to the agenda

### Item 5 - Agreement of the draft minutes from WG-V-2014

### Meeting documents:

- WGV2014\_APCP\_6-1\_Draft minutes updated
- WGV2014\_APCP\_6-2\_Draft minutes updated
- WGV2014\_APCP\_6-3\_Draft minutes updated
- WGV2014\_APCP\_6-4\_Draft minutes updated

For agreement

#### Item 6 - Discussion of active substances

#### 61 PHMR

### 6.1.1 PHMB – substance identification criteria for polymeric substances

For discussion

### 6.1.2 PHMB (eCA FR)

PT 01, 02, 03, 04, 06, 09, 11

Meeting document: WGI2015\_APCP\_6-1 Previous discussion(s): WG III 2014

For discussion/agreement

### 6.2 Cyromazine (eCA EL)

PT 18

Meeting document: WGI2015\_APCP\_6-2

Previous discussion(s): TM II 2012

For discussion/agreement

Item 7 - AOB

### 7.1 Lessons learned

SECR/WG members to reflect on the experience gained

## Human Health Working Group Chair: Antero Airaksinen

### Item 1 - Welcome and apologies

### Item 2 - Administrative issues

For information

### Item 3 - Agreement of the agenda

For agreement

### Item 4 – Declarations of potential conflicts of interest in relation to the agenda

### Item 5 - Agreement of the draft minutes from WG-V-2014

Meeting documents:

- WGV2014\_TOX\_6-1\_Draft minutes
- WGV2014\_TOX\_6-2\_Draft minutes
- WGV2014\_TOX\_6-3\_Draft minutes
- WGV2014\_TOX\_6-4\_Draft minutes
- WGV2014\_TOX\_6-5\_Draft minutes
- WGV2014\_TOX\_minutes\_draft.docx

For agreement

#### Item 6 - Discussion of active substances

### 6.1 Cyromazine (eCA EL)

PT 18

Meeting document: WGI2015\_TOX\_6-1 Previous discussion(s): TM II 2012

For discussion/agreement

### 6.2 PHMB (eCA FR)

PT 1, 2, 3, 4, 6, 9, 11

Meeting document: WGI2015\_TOX\_6-2

Previous discussion(s): None

For discussion/agreement

### Item 7 – Technical and guidance related issues

### 7.1 Update on guidance development (ECHA)

SECR to inform

For information

### 7.2 Update on Ad hoc Working Group - Human Exposure

SECR to inform

For information

### (a) Recommendation of the Ad hoc Working Group - Human Exposure

Non-professional use of antifouling paints: exposure assessment for a toddler

Meeting document: WGI2015\_TOX\_7-2a\_non-prof\_antifouling\_toddler.docx

For agreement

### (b) Recommendation of the Ad hoc Working Group - Human Exposure

Methods and models to assess exposure to biocidal products in different products types

Meeting document: WGI2015\_TOX\_7-2b\_methods\_models.docx

For agreement

### 7.3 Update on Ad hoc Working Group - Assessment of Residue Transfer to Food

SECR to inform

For information

Item 8 - AOB

### 8.1 Lessons learned

SECR/WG members to reflect on the experience gained

### **Efficacy Working Group**

### **Chair: Ann Thuvander**

### Item 1 - Welcome and apologies

#### Item 2 - Administrative issues

### Item 3 - Agreement of the agenda

For agreement

### Item 4 – Declarations of potential conflicts of interest in relation to the agenda

### Item 5 - Agreement of the draft minutes from WG-V-2014

- WGV2014\_EFF\_6-1\_draft\_minutes.docx
- WGV2014\_EFF\_6-2\_draft\_minutes.docx
- WGV2014\_EFF\_6-3\_draft\_minutes.docx
- WGV2014\_EFF\_6-4\_draft\_minutes.docx
- WGV2014\_EFF\_draft\_minutes.docx

For agreement

### Item 6 - Discussion of active substances

### 6.1 Cyromazine (eCA EL)

PT 18

Meeting document: WGI2015\_EFF\_6-1

Previous discussion(s): None

For discussion/agreement

### 6.2 PHMB (eCA FR)

PT 1, 2, 3, 4, 6, 9, 11

Meeting document: WGI2015\_EFF\_6-2

Previous discussion(s): None

For discussion/agreement

### Item 7 – Technical and guidance related issues

### 7.1 Part C of the Efficacy Guidance

For discussion

### 7.2 'Role of Efficacy'

Meeting document: WGI2015\_EFF\_7-2

For discussion

### 7.3 PT 8

Meeting document: WGI2015\_EFF\_7-3

For discussion/agreement

### 7.4 Update on guidance development

Meeting document: WGI2015\_EFF\_7-4

For information

### Item 8 - AOB

### 8.1 Update on working procedure for approval of active substances

For information

### 8.2 Lessons learned

SECR/WG members to reflect on the experience gained

### **Environment Working Group**

### **Chair: Heike Schimmelpfennig**

### Item 1 - Welcome and apologies

#### Item 2 - Administrative issues

### 2.1 Virtual meeting tool

For information

### Item 3 - Agreement of the agenda

For agreement

### Item 4 – Declarations of potential conflicts of interest in relation to the agenda

### Item 5 - Agreement of the draft minutes from WG-V-2014

### Meeting documents:

- WGV2014\_ENV\_6-1\_Draft minutes updated
- WGV2014\_ENV\_6-2\_Draft minutes updated
- WGV2014\_ENV\_6-3\_Draft minutes updated
- WGV2014\_ENV\_Draft minutes updated

For agreement

### Item 6 -Technical/guidance related issues

### 6.1 Clarification of remaining open points following the consultation of the draft ESD for PT 19 (ECHA)

Meeting document: WGI2015\_ENV\_6-1

For discussion

### 6.2 PT 2 - Ad hoc EE WG consultation on scenarios to assess biocides as PT02 for private pool treatment (FR)

Meeting document: WGI2015 ENV 6-2

For discussion

### 6.3 Update on guidance development, e-consultations and issues to be sent to the Ad hoc EE WG (ECHA)

Meeting document: WGI2015\_ENV\_6-3

SECR to inform

For information

### Item 7 - Discussion of active substances

### 7.1 PHMB (eCA FR)

PT 1, 2, 3, 4, 6, 9, 11

Meeting document: WGI2015\_ENV\_7-1

Previous discussion(s): None

For discussion/agreement

### 7.2 Cyromazine (eCA EL)

PT 18

Meeting document: WGI2015\_ENV\_7-2 Previous discussion(s): TM II 2012

For discussion/agreement

### Item 8 - AOB

### 8.1 Lessons learned

SECR/WG members to reflect on the experience gained